BiOrion runs two active lead development programs.

In the diagnostic imaging program 68Ga-BOT5035, Thorascan®, a first generation dimeric PDGF beta receptor binding bicyclic peptide is conjugated to NOTA, that chelates the PET radionuclide Gallium-68. In addition to cardiac fibrosis (HFpEF and AFib), BOT5035 will be developed for diagnostic imaging of pulmonary fibrosis (ILD and IPF), allowing disease monitoring of therapeutic strategies.

In the diagnostic imaging program 68Ga-BOT1712, Hepatoscan®, a second generation PDGF-ß-receptor binding single domain antibody is conjugated to NOTA, that chelates the PET radionuclide Gallium-68. BOT1712 is developed for diagnostic imaging of NAFLD/NASH-induced hepatic fibrosis and the theranostic targeting of advanced colon cancer. First-in-man PET-imaging studies with 68Ga-BOT1712 are anticipated for 2023. BOT1712 will eventually be further developed for targeted radiotherapy with 177Lutetium of advanced colon cancer with active fibrotic-stroma. 

Novel diagnostic imaging tracers based on our sdAbs discovery engine for PDGFRA, IGF-1/2R and EGFR will be further developed towards lead programs.